Fibers and Gut Health

NCT02234518 | Completed

• 1 other identifier: 12.04.NRC
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Gastrointestinal discomfort regularly affects \>25% of the population worldwide. One of the major contributors to GI discomfort is constipation, which has a prevalence of \~15% and symptoms of which have a significant negative impact on the sufferer's quality of life. One of the hallmarks of chronic constipation is slow progression of contents through the gut (i.e. slow gut / colonic transit time), which may be associated with hard stools that are difficult to expel. Dietary fiber supplements are widely used as a first-line treatment for constipation although little Level 1 evidence exists to support its use in adults. The effectiveness of different fiber supplements is difficult to compare given wide differences in water-retention capabilities and effects on the colonic microbial ecology. Given the promising, yet largely unsubstantiated, benefits of fiber supplementation on symptoms of functional constipation, the objective of this clinical trial is to evaluate tolerance and effectiveness of four week supplementation of a fiber product, in a dose-ranging fashion, on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.

Conditions

Constipation

Outcome Measures

Primary Outcomes (1)

• Whole gut transit time

  To evaluate change in whole gut transit time 2 weeks after consumption of the study product in constipated patients consuming the study product containing fiber in high quantity, compared to those consuming placebo

  After 2 weeks consumption of the study product

Secondary Outcomes (4)

• Gastrointestinal symptoms

  After 2&4 weeks consumption of the study product

• Regional colonic transit time

  After 2 weeks consumption of the study product

• Whole gut transit time

  After 2 weeks consumption of the study product

• Tolerance

  After 1&2&4 weeks consumption of the study product

Other Outcomes (2)

• Adverse Events

  Through the study product consumption period (4 weeks)

• Gut Health Insight Survey

  At screening, after informed consent

Study Arms (3)

High quantity fiber food product

EXPERIMENTAL

Other: High quantity fiber

Low quantity fiber food product

EXPERIMENTAL

Other: Low quantity fiber

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

High quantity fiber OTHER

The intervention type is food product

High quantity fiber food product

Low quantity fiber OTHER

The intervention type is food product

Low quantity fiber food product

Placebo OTHER

Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men or women aged 18-75; female subjects of child-bearing potential must be willing to use a reliable method of contraception throughout the study period
• BMI: 18.5 - 29.9 kg/m2
• Recruitment based on simplified core ROME III diagnostic criteria for functional constipation (based on specific screening questions):a). average Bristol stool type of 1 - 4 AND frequency of 1 - 3 spontaneous bowel movements (SBMs) per week b). plus at least ONE of: straining on at least 25% of defaecations; sensation of incomplete evacuation on at least 25% of defaecations; sensation of anorectal obstruction / blockage on at least 25% of defaecations; use of manual manoeuvres on at least 25% of defaecations
• Cleveland Clinic constipation score (CCCS) of 8-20
• Low-moderate fiber intake (≤18g) determined by the semi-quantitative food intake screener known as the Block Fiber Screener
• Ability to understand the patient information sheet and instructions in Dutch, and able to provide informed consent

You may not qualify if:

• Subjects who report lactose intolerance and/or are allergic to soy or cow milk protein
• Pregnant or breast-feeding women
• Ongoing other diagnosed gastrointestinal disease or complication (Crohn's disease, Coeliac disease, chronic diarrhoea)
• Any clinical relevant abnormalities in the screening visit medical examination or alarm features such as sudden unintentional weight loss, rectal bleeding, recent change in bowel habit (\<3 months), abdominal pain and stool positive for occult blood
• Prior abdominal surgery (including gastric bypass or laparoscopic banding), except cholecystectomy and appendicectomy
• Neurologic diseases such as multiple sclerosis, stroke, spinal cord injury, Hirschsprung disease
• Chronic medication that in opinion of the investigator would impact gut motility
• Illness that may preclude the subject's ability to complete the study or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness, severe cardiovascular disease, chronic renal failure or eating disorders) or any other serious illness resulting in \>2 weeks inability to work in the 3 months before the study start
• Subjects with co-morbid illnesses such as cardiovascular, endocrine, renal or other chronic disease likely to affect gut motility or limit normal functions (e.g. reduced mobility or increased fragility)
• Ongoing alcohol, drug, or medication abuse (anamnesis only)
• Self-reported symptoms of pelvic organ prolapse
• Moderate or severe active local anorectal problems such as recurrent anal fissures, bleeding, large prolapsing haemorrhoids
• Regular use of fiber supplementation (e.g. Fybogel, Lactulose) (i.e. no more than 1 standard dose) over the week prior to the screening visit and no more than 6 standard doses in the past 1 month prior to the screening visit
• Participation in another study with any investigational product within 3 months of screening
• Investigator believes that the participant is physically or mentally unfit to participate in the trial

Sponsors & Collaborators

• Société des Produits Nestlé (SPN): lead

Study Sites (1)

Julius Clinical

Zeist, 3703 CD, Netherlands

Location

MeSH Terms

Conditions

Constipation

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Diederick E. Grobbee, Prof, MD, PhD

  Julius Clinical

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 2, 2014
• First Posted: September 9, 2014
• Study Start: October 1, 2014
• Primary Completion: October 1, 2015
• Study Completion: October 1, 2015
• Last Updated: November 10, 2015

Record last verified: 2015-11

Locations

NL (1)